Emory Univ — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$627,253	80
2023	Research	$125,907	20
2022	Research	$173,207	23
2021	Research	$110,420	22
2020	Research	$121,742	25
2019	Research	$334,032	46

Breakdown

Who paid Research payments · program years 2019–2024

Janssen Research & Development, LLC $1,040,624 187 payments
Novo Nordisk AS $376,589 25 payments
Merck Sharp & Dohme Corporation $72,493 1 payment
Janssen Scientific Affairs, LLC $2,754 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $100 1 payment

Studies the money was for Research payments · program years 2019–2024

A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder $189,555 27 payments
Haem-4436 $123,064 9 payments
17000139Blc2002 $113,259 26 payments
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus $111,223 26 payments
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events Hospitalization and Death in Medically Ill Outpatients With Acute Symptomatic Coronavirus Disease 2019 COVID19 Infection $95,012 13 payments
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone DRd versus lenalidomide and Dexamethasone Rd in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant $92,847 7 payments
A Multi Center prospective long term observational registry of pediatric patients with inflammatory bowel disease $81,849 11 payments
A multi center prospective long term observational registry of pediatric patients with IBS $75,418 7 payments
Evaluation of Tumor Microenvironment and Strategies to Break anti-PD1 Resistance Using Combinatorial Approaches with Radiation. $72,493 1 payment
A Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma who are not eligible for high dose chemotherapy and autologous stem cell transplant $57,623 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.